The concept of patient-centricity has come a long way in the past few decades. However, applications of patient-centricity in intervention development remain inconsistent. Critics have questioned the validity of patient-centric claims that are seen as performative checkbox exercises. Patients surveyed largely think that pharma has little regard for their perspectives, believing corporate priorities are instead driven by profits.
A new book compiled by the Patient Centered Solutions team at IQVIA gathers insights on patient-centric intervention development from a diverse group of more than 30 experts. These contributors include pharma company executives, biotech manufacturers, regulatory representatives, patient representatives, patient advocacy group (PAG) leaders, patient experience data (PED) researchers, and payer and health technology agency (HTA) advisors.
In formats ranging from reviews of the research and personal narratives to poetry and short fiction, the contributors share their thoughts on where patient-centricity stands today, what improvements are still to be made, and how the voice of the patient will influence the future of healthcare. Key themes explored in the book include:
Explore the complete listing of chapters and contributors ›
- Why patient-centricity efforts must extend beyond the collection of patient experience data (PED)
- How the biopharmaceutical industry can involve patients as true research partners
- Why the industry must account for patients’ heterogeneous experiences
- How the industry can sustain patient partnerships by establishing their return on investment
Access the free book download by filling out the form below
About the editor
Matthew Reaney, PhD, C.PSYCHOL, C.SCI, MSc, AFBPSS
Global Science and Analytics Lead, IQVIA Patient Centered Solutions
Head of the Patient Centered Solutions Institute, IQVIA
Dr. Matthew Reaney has spent much of his life in and around the healthcare system. He is a son, spouse and parent of remarkably resilient people who live with chronic diseases that involve significant self-management, and he is passionate about helping them use their voices to inform healthcare decisions. It was with this in mind that he embarked on his first role in patient-centered care and patient-focused research more than 20 years ago. He has held positions in pharmaceutical companies, universities, charities, consultancies and hospitals since — sometimes simultaneously — advocating for the patient voice to be heard in intervention design and testing, and in clinical care decision-making. In his role at IQVIA, Matt sets scientific direction for the Patient Centered Solutions team and oversees a variety of qualitative and quantitative research projects and patient-focused communication activities.
Complete listing of chapters
Chapter 1
Patient-centricity in the biopharmaceutical industry: Are we nearly there yet? Why are you even asking this question?
Chapter 2
Patient-centricity in drug development: Past milestones, present state and future opportunities from the regulatory professional’s perspective
Chapter 3
The center of focus
Chapter 4
From participants to partners: Elevating the patient voice in modern drug development
Chapter 5
Will we ever achieve sustainable adoption of patient engaged planning and execution?
Chapter 6
From minor to major impact, how patients are increasingly shaping the world of industry drug development
Chapter 7
Patient-centricity now: People, action and culture
Chapter 8
Patient-centricity: When you are all-in-one
Chapter 9
The full-court press: Advancing patient experience data in oncology
Chapter 10
Patient-centric treatment tolerability: Past, present and future
Chapter 11
A decade in: Reflections from the field
Chapter 12
The state of patient-centricity in drug development is strong and getting stronger! But we all have work yet to do…
Chapter 13
Why patient-centricity is not fit for purpose: Mutual investment, the new people-centric research and advocacy
Chapter 14
United in purpose and founded in trust: Transforming clinical research through grassroots initiatives
Chapter 15
Voices of experience: Enhancing clinical trials through patient and site engagement
Chapter 16
The missing voice: Why patient perspectives must drive MS drug development
Chapter 17
The road to co-creation: Patients and pharma shaping the future of clinical research
Chapter 18
Patient advocacy group and pharmaceutical industry collaboration to drive patient-centric practices and accelerate the development of new medicines
Chapter 19
Cautious optimism: My experience in pushing the patient-first narrative throughout biopharma
Chapter 20
It’s the economy, stupid: Drug developers will invest in patient-centricity when the R&D economics are clear
Chapter 21
Patient-centricity: Reflections from a former academic, consultant, regulator and now patient representative
Chapter 22
Peering beyond the slogans and assumptions: Are companies sincere about the patient voice in drug development?
Chapter 23
Patient experience of what?
Chapter 24
A reality check on patient-centricity: The good, the bad and the ugly
Chapter 25
The luminous science of us: Healing beyond the algorithm
Chapter 26
Editorial: Moving from “patient-centricity” to “patient partnerships” to serve intervention development